Condition: Non-Small Cell Lung Cancer With EGFR Mutation · Sponsor: Abbisko Therapeutics Co, Ltd
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.
This description comes directly from the study's public registry record.
Yuan Lu · +86-21-68910052 · clinical@abbisko.cn
Yinan Lin · +86-21-68910052 · yinan.lin@abbisko.com
Always discuss trial participation with your own doctor first.
| Hanhui Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Union Hospital Tongji Medical College Huzhong University of Science and Techology | Wuhan, Hubei, China | Not Yet Recruiting |
| Jilin Cancer Hospital | Changchun, Jilin, China | Not Yet Recruiting |
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06668103